News

Press Release: What’s eating the erythrocytes?

A recent press release on the Penn Medicine News Blog explains a study which “further support[s] the concept that complement inhibition at the level of C3 rather than C5 will hopefully confer better therapeutic benefits for PNH patients because it will prevent destruction of red blood cells both inside and outside of vessels.” Such a therapeutic possibility is compstatin, a C3 inhibitor drug in development that was recently licensed by Amyndas Pharmaceuticals. Clinical trials for the resulting drug candidate are set for 2015 and 2016.To read entire press release: news.pennmedicine.org

Amyndas participates in a major publication on Paroxysmal Nocturnal Hemoglobinuria (PNH)

A new review article titled ”A complement C3-targeted complement inhibitor reaching its prime for bedside intervention” by Mastellos et al., has been accepted for publication in the European Journal of Clinical Investigation. The review analyzes why complement component C3 represents an attractive target for therapeutic modulation of the complement cascade and describes in detail the optimization effort which has led to the structure-function refinement of compstatin and its novel derivatives such as AMY-101, with improved inhibitory potency, pharmacokinetic profile and efficacy in a number of clinically relevant primate models of disease. The review discusses translational challenges in complement drug discovery and peptide drug development and analyzes concerns related to systemic C3 interception; despite existing challenges AMY-101 emerges as a highly promising complement inhibitor therapeutic.

Amyndas features in two of the widest-read Greek national Sunday newspapers

As a winner in the 2015 “Innovation Project” organised by the Association of Pharmaceutical Companies in Greece, Amyndas enjoys significant exposure in the local press and media in Greece. The science news source from two Greek Sunday newspapers, Kathimerini (November 16, 2014) and Makedonia (November 23, 2014) posted an informative profile of Amyndas, describing the company’s novel technology licensed from the Universiy of Penn, the wide range of potential therapeutic applications and the profound impact that these new therapies can have for patients and health care systems internationally. The articles (in Greek) created significant reader’s interest and can be accessed at: http://www.kathimerini.com.cy/index.php?pageaction=kat&modid=1&artid=189465&show=Y (newspaper Kathimerini) and http://www.makthes.gr/news/reportage/129900/ (newspaper Makedonia).

Amyndas wins pharmaceutical innovation competition (ΣΦΕΕ Innovation Project 2.0)

The “Innovation Project” is an open call competition organized by the Association of Pharmaceutical Companies in Greece, designed for small companies, spin-offs, entrepreneurs and researchers in the sector of pharmaceutical and bioscience innovation in Greece. The competition is sponsored by a group of large pharmaceutical companies active in the Greek market (Abbvie, Pharmaserve-Lilly, MSD, Novartis, Roche, Pharmathen, Chiesi and Genesis). The competition aims at strengthening the business capabilities of small companies, entrepreneurs and researchers, with pioneering ideas and innovative proposals in the biosciences, pharmaceutical and healthcare sector, while promoting extroversion and the competitive presence of these emerging players in the international markets. Amyndas entered this 2-stage competition and won a prize for “Original Pharmaceutical Innovation”. In addition to the monetary award Amyndas is eligible to receive a range of supportive services, such as advice on small company development, on regulatory and clinical development, as well on raising funds, or gain access to training centers and R & D. For the original article in Greek, click here.

Press Release: FDA grants orphan drug designation for PNH to Amyndas Pharmaceuticals’ novel complement inhibitor

“Amyndas Pharmaceuticals SA, the complement therapeutics company, announced that the U.S. Food and Drug Administration (FDA) has granted AMY-101, a potent complement C3 inhibitor, an Orphan Drug Designation for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The U.S. FDA orphan designation comes after the European Medicines Agency (EMA) orphan status approval of AMY-101 for the same indication, less than 2 months ago.”

Amyndas features in ΒΗΜΑ, on of the widest-read Greek national Sunday newspapers

ΒΗΜΑ Science, the science news source from Greek Sunday newspaper BHMA, on September 7, 2014, posted an extended and informative interview of Amyndas pharmaceuticals founder, Prof John Lambris. In this article, which aimed at communicating the results of Prof Lambris’ scientific research to the public, Amyndas’ promising new drugs and their potential therapeutic applications are presented for the first time in a widely-read national Greek newspaper, conveying the profound impact that these new therapies can have for patients and health care systems internationally. The article created significant interest, with its wide readers’ audience commending and responding enthusiastically, hoping that these new therapies to be brought to patients soon. The article can be accessed here.

Press Release: EMA grants orphan drug designation for PNH to Amyndas Pharmaceuticals’ novel complement inhibitor

EMA grants orphan drug designation for PNH to Amyndas Pharmaceuticals’ novel complement inhibitor. Amyndas Pharmaceuticals SA, the complement therapeutics company, announced that the European Medicines Agency (EMA) has granted AMY-101, a potent complement C3 inhibitor, an Orphan Drug Designation for the treatment of Paroxysmal Nocturnal Hemoglobinuria. – PR12364497

Amyndas features in BioWorld, the biopharmaceuticals news source from Thomson Reuters

Amyndas features in BioWorld, the biopharmaceuticals news source from Thomson Reuters: Amyndas recent developments caught the interest of the international press, with BioWorld publishing an article about Amyndas on July 17. In this article, Amyndas is presented as an emerging company aiming to create novel therapeutics to treat complement-mediated disorders, that could be more potent than other complement inhibitors. The article titled “Two- pronged Amyndas targets complement-based anti-inflammatories” can be accessed at: http://www.bioworld.com/content/two-pronged-amyndas-targets-complement-based-anti-inflammatories

Press Release: Penn team identifies promising new target for gum disease treatment

University of Pennsylvania researchers have been searching for ways to prevent, halt and reverse periodontitis. In a report published in the Journal of Immunology, they describe a promising new target: a component of the immune system called complement. Treating monkeys with a complement inhibitor successfully prevented the inflammation and bone loss that is associated with periodontitis, making this a promising drug for treating humans with the disease.